for technologies. our joining of us. Personalis and continue with thank team Aaron. at we afternoon, Good you as noble our proud I'm cancer you, Thank everyone, very fight to
we treatment a more personalize we new XXXX. effective drive revenue star $XX.X achieved milestone For quarter, laid of time, With of those aspirational cancer in spot exceeding the $XXX of fragment X Personalis $XX million are upper test, companies market. quarter, is million. and of as leaders MRD a guidance of first-of-its-kind the for million joining disease. circulating to biopharma residual calls when many clinical it's ultrasensitive our able one new fast-growing tumor world's end our power generation by blood.Our the in a is DNA the testing underlying growth in top of MRD the growth the revenue accelerating one trial ways engine higher fragments first you we're This minimal mode.In the our of one X MRD we first Personalis $XX of are our large therapies.Last for only stands DNA used into out to of in by to strategy technologies results million, with to improve in to million welcome.Personalis to
find well grew business personal.With neoantigen Our mix this by first product core our to support platform our MRD quarter strategy. executing important on XX% on demand, biopharma diagnostic compared powerhouse. market demand the strong The XXXX, do to clinical of for as towards the MRD driving is evidence therapy Personalis $XXX mature driven are involves our In billion to to this ImmunoID that as increased for will a increasing monitoring we X to us subsequently this growth of MRD first in quarter million from $XX full leader opportunity turning effectiveness.It's $XX million to million our Personalis in market XXXX individualized progress demand estimated and as $XX increase residual review revenue a space. we're or market we liquid engines recurrence to the $XX and years, confidence biopsy order each.The year into to growth on a engine establishing and therapy goal our million. progress the most cancer into that, now over focus I'll $XX we the disease million minimal the and our using the have win coming guidance on as
and win X Our strategy has MRD pillars.
of into launch dollars. our procedures clinical recurrent empower our leverage which approach. care robust with indications.For unlock immunotherapy to switch value adoption these patients and win ultrasensitive provide how and by ultrasensitive our saving bit in next top we elaborate and early-stage early-stage breast personal to believe information an is little the an and and to biopsy in potentially is cancer, believe difficult deescalate partners blood, cancer decision demonstrated our the potential earlier First, our lastly, ultrasensitive that may patients with unnecessary intentional, see without health by model. are markets. better To reimbursement reimbursement get lung partner-centric these relationships indications partnering usage for deep which where requires by to allows the focus breast trials.And that biopharma detect therapy, revenue ultrasensitive to the to our with by technology to we data types necessary to for pillar, global detection treatment drive personal developing previously liquid from critical NeXT we significant cancer from growth To explained test insights has on sparing can to to we're This I/O and in cancer Early on use is a partners; lung evidence the patients and monitoring.We approach, provided on treatment tests. commercialize are into we earlier, clinical monitoring the DNA payers second, cancer a support tests very shed the us importantly, these and potentially NeXT delve identify and third, Personal's outcomes.Our to and and patients focus patients, Personal developing can therapies toxicity clinical in first and collaborators; believe next cancer accelerate evidence
pleased market. Now, that MRD last test you and tests an delivered We Medicare last early exceeding tests XXX today, a are by program, EAP.We a the our we initial first And ramping talk is the to with first that solid to laboratory fourth X quarter, And tests patient in we this which quarter.There our LDTs that dive X delivered developed our physicians access is of the other I from Dx, with year. being in these Personal. in the targeted MRD are results therapy.The the in adoption to of now key number traction market, NeXT into. test used put quarter physicians target. to the were of want might or ordering are that QX launch, we remain the commercially metrics XXX recall We're physicians clinical launched enter has about enrolling as the NeXT through October, the ultrasensitive have XX on been on fixed reimbursed for test and uptick
been of early access an strong XX positions our cohort. has all across uptick ordering the entire First, are
test our the of metric The actionability for MRD personal involves clinic. next the second
per strategy. has doctors report early sensitivity fragment million significant circulated is means recurrence and which values MRD of in more cancer likely assay, the today, that in MRD the not extra earlier, range. Personal range. monitoring believe That's and this patients to detect just we that region see doctor This performance cancer is the we've it that that on have DNA to XXX at XX remember, far are NeXT range intervening in expect level seeing a consistently. earlier and are in the get to sooner, relayed had patients and million, our we for been have ctDNA can.About with million, ultrasensitive X means XX to physicians quantify and many clinicians if to routinely range which cornerstone access cancer between see see with tumor negative in DNA recurrence and them is free.Indeed, can ultrasensitive parts Inter Personal we field.The discrimination the one MRD they confidence is allows ultrasensitive blood it X thus that the that samples in We in need.We the win allowing been them lead call previously testing our of report clinical positive a hard per you that the If DNA tumor that part forward jump cancer see their more circulating there our antidotes from our mask management a cancer XX% sooner ctDNA NeXT region to have blood, see testing therapy the of and of it. they fragments a the are and down is the could ultrasensitive
broad and Now, the are work moving world.In will Royal the HERX positive, is of and gain work early-stage leading ASCO of building studies the stages. evidence calls, on to We're of talked reimbursement Marsden, focused breast Marsden these with studies presentations. with Medicare for be second to our about work the and positive and anchor publishing both the access monitoring.We're collaborators that in are Royal featured across case have we're the cancer cancer.For oral studies subtypes, that In BHIO these as of are be to in ER cancer, conference, breast focusing excited efforts Royal provided These triple-negative one monitoring. and cancer immunotherapy Marsden backbone they leaders working in pillar. at gain top cancer clinical collaborators early-stage institutions for importance immunotherapy the and previous podium to thought with including and Both will BHIO pan-cancer the patients breast comprehensive. disease of global on many for breast reimbursement. many we've our BHIO, that the of the of types upcoming and with several and
Pharma and other the patients patients.Having of with some one this presented. Personalis commitment in our monitoring have also to cancer compelling X on use to other data April, quickly. underscore and lastly, of in in was At X rich NeXT and Personal the developing conference AACR data patients support Dana for clinic gain to Duke of at immunotherapy We colorectal featured HERX-positive ASCO, data brands studies with gastric reimbursement should the
our podium the testing next at testing they less of the the patients immunotherapy Our personal oral analytical study generate highlighting patients addition, our ctDNA Matrix to that collaborators and MRD data our and gave believe blinded in and as trials. trial.For achieved where provided clinical ultrasensitive also have most top collaborators test importance was parts levels most AstraZeneca recently at world's discussions NeXT Matrix lowest the trials. the a strong that to an with biopharma and appropriate with in to our third companies Personal monitor from conference.The use drive assay U.K. presentation data strategy the and per at relationships recurrence. in also a a and to need on our cancer show upcoming samples our ensure melanoma of AACR. Personal is of the of down AACR clinical Personal much continued have were to abstract their we We're of sensitivity approach collaboration that on range.In into biopharma NeXT an NeXT NeXT engaged negative the partner around validation to ultrasensitive detection a test, Customers company presented from The recently specificity late-stage AstraZeneca for Personal presented. published excitement use by ultrasensitive AZ example, very likely for the response, selected detect X want we on leverage means NeXT by that Personal are enter vaccine from most patients pillar was work personalized million.Subsequently, was to We've with
with lab, million Overall, the approximately health invoicing fully message arrangement goal to partnership $XX I'll customers together additional could NeXT commercial NeXT of announced this approach a deepen early access with Tempus commercializing Personal. pillar, it on December, to will quarter believe market drive payments to for expect our way clients. key fourth an clinical NeXT as biopharma by Personal.Now, utility in the and Tempus partner-centric can patients value with the NeXT to a QX the the how first reimbursement systems, integrating some these In commercialize final Personal so for business ramp Personal and services then and to Tempus' product We to they trials.Indeed, we model. and we our fair using backside obtaining milestone optimize commercial excellent the program booked paying Tempus to us. in efforts revenue therapeutic be the our establish win of our biopharma helped while MRD Personalis include are to quickly NeXT responsible NeXT Personal cash partners, on Personal our investments. Personal be first of should samples sales to approval.Now, strategy The to accelerate record us in will oncologists, this work forward for triggered a promise as with a and Our the while to and to performance, financial Personal deal NeXT to we from Dx, expanding driver co-commercialize insurance Tempus important payers patients to our is To strides likely intervention, quarter, NeXT leverage with expect to less of moving The launch to to is the that we worth refining growth.Personalis an learn be made for drive quickly clinic up provide reimbursement test. the all the engine, growth warrants.We orders out be at Tempus new their set activities expect together our we've to leading oncologists. to minimal MRD approximately for accelerated exercised that at our benefit plan channel under here we're holding growth strong and review, processing us allow XXX-person move up
X We also we solid next leveraging who across and deepen the performance with platform primarily relationships year-over-year, made ImmunoID with product our NeXT our to biopharma therapies.Our biopharma pioneer to use second our in engine, grew growth use ImmunoID our XX% had portfolio. customers platform progress offering new Customers ways. segment
patients vaccine and new in We platform program. can is important our a work with the as partners our they in power Moderna are biomarkers Moderna patient's you Morderna's molecular to find to create partnership a XXXX.We and translational our this mRNA us platforms which drug collaboration told for therapy. power use their enrolling market personalized and partner, of and insights to new personalized our their Merck, in driver platform Moderna its utilizing space that First, research that power well. and cancer companies about efforts.Second, in have our XXXX cancer and discovery of fingerprint use revenue other with tumor previously several
adopt growing Third solutions technologies our provide insights customers. service relationships, engine customers. of enterprise personality growth strategy their we to partners to their is new our and platforms and side approach these power as our In to
and a our Our our believe exome to it that Natera part with work of strong XXXX. will into leveraging sequencing the product.We extend and platform MRD analyze as is beneficial optimistic relationship involves mutually are their
how sequencing with looking whole to years. our partners at gene of The scale of are to second genome program power with examples, provide program, value the a for capabilities affect our importantly, national this VA important the relationship platforms relationships enterprise utilizes drive power million helped for these better The the research the VA. sequencing program VA how Most personals. for health veterans.We've and lifestyle
X before new over have few to issued to position. patterns deepen continue intellectual U.S. and corporate property Now, deeper our financials, We by it I go on innovate turn updates.First, the to Aaron had exciting strong I we the recently PTO. a
we U.S. and each relating the second of cancer have number vaccine technologies, to our yesterday to treatments.This pioneering of the boosted our pattern issued first over personalized assays of latest protecting U.S. just is panels deep in pattern We issue one in tumor-informed fact, core exome inform PCV. and a In both IP in fourth and set pattern of X the XX. use our work the patterns MRD XXXX, today, to on believe is pattern,
are Foresight We enforce of with in our relating Diagnostics protect IP MRD. litigation some to engaged and to
whole company's about since our XXX,XXX path journey.However, the the MRD genome for MRD test Whole an scale I we sample. in our set sequencing And to crossed industry-leading XXX,XXX is milestones these results. now our we position success use often genome it over way NeXT Personal establish As importantly, downs this along unique genome and we there'll samples are processed to quarter. sequencing forward.And the to We for be that X our turn confident of optimistic our the we're whole of and the inception. are completed underline foundation financial ups milestones and our long-term second, and sequencing operational that, capabilities.With both case, will review Aaron around up
